Bluejay Diagnostics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Bluejay Diagnostics and similar public comparables like Epigenomics, Biora Therapeutics, Odyssey Health, Sunniva and more.

Bluejay Diagnostics Overview

About Bluejay Diagnostics

Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay’s first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from ‘sample-to-result’ to help medical professionals make earlier and better triage/treatment decisions.


Founded

2015

HQ

United States

Employees

7

Financials (FY)

Revenue: -
EBITDA: ($7M)

Market Cap

$1M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Bluejay Diagnostics Financials

Bluejay Diagnostics reported last fiscal year revenue of - and negative EBITDA of ($7M).

In the same fiscal year, Bluejay Diagnostics generated ($7M) in EBITDA losses and had net loss of ($7M).


Bluejay Diagnostics P&L

In the most recent fiscal year, Bluejay Diagnostics reported revenue of - and EBITDA of ($7M).

Bluejay Diagnostics is unprofitable as of last fiscal year, with EBITDA margin of - and net margin of -.

See analyst estimates for Bluejay Diagnostics
Last FY202320242025202620272028
EBITDA($7M)($10M)($7M)($7M)
Net Profit($7M)($10M)($8M)($7M)

Financial data powered by Morningstar, Inc.

Bluejay Diagnostics Stock Performance

Bluejay Diagnostics has current market cap of $1M.


Bluejay Diagnostics' stock price is $1.06.

Bluejay Diagnostics has an EPS (earnings per share) of $-6.62.

See more trading valuation data for Bluejay Diagnostics
Market CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$1M1.0%---$-6.62

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Bluejay Diagnostics Valuation Multiples

Bluejay Diagnostics trades at 0.4x EV/EBITDA.

See NTM and 2027E valuation multiples for Bluejay Diagnostics

Bluejay Diagnostics Financial Valuation Multiples

As of August 14, 2026, Bluejay Diagnostics has market cap of $1M.

Bluejay Diagnostics has a P/E ratio of (0.2x).

Last FY202320242025202620272028
EV/EBITDA0.4x0.3x0.4x0.4x
EV/EBIT0.4x0.2x0.3x0.4x
P/E(0.2x)(0.1x)(0.1x)(0.2x)
EV/FCF0.4x0.3x0.3x0.4x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Bluejay Diagnostics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Bluejay Diagnostics Margins & Growth Rates

See estimated margins and future growth rates for Bluejay Diagnostics

Bluejay Diagnostics Growth Rates

23/2424/2526/2727/2828/29
EBITDA Growth(30%)(0%)
EBIT Growth(30%)(3%)
Net Profit Growth(22%)(11%)
FCF Growth(10%)(23%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Bluejay Diagnostics Operational KPIs

Bluejay Diagnostics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.0M for the same period.

Access forward-looking KPIs for Bluejay Diagnostics
Last FY202620272028
Revenue per Employee$0.0M
Opex per Employee$1.0M

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Bluejay Diagnostics Competitors

Bluejay Diagnostics competitors include Epigenomics, Biora Therapeutics, Odyssey Health, Sunniva, Bone Biologics, Luxbright, Brain Scientific, Integragen, Inhalation Sciences SWE and EvokAI.

Most Bluejay Diagnostics public comparables operate across Diagnostics & Genomics, Medical Devices, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Epigenomics499.8x-(38.2x)-
Biora Therapeutics----
Odyssey Health--(2.2x)-
Sunniva----
Bone Biologics--1.0x-
Luxbright0.8x0.8x(0.6x)(0.5x)
Brain Scientific14.2x-(0.4x)-
Integragen0.0x-(2.6x)-

This data is available for Pro users. Sign up to see all Bluejay Diagnostics competitors and their valuation data.

Start Free Trial

Bluejay Diagnostics VC Funding History

Before going public, Bluejay Diagnostics raised $3M in total equity funding, across 2 rounds.


Bluejay Diagnostics Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Jun-21SeedCentrecourt Asset Management$1M--
Apr-17Seed-$2M--

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Bluejay Diagnostics

When was Bluejay Diagnostics founded?Bluejay Diagnostics was founded in 2015.
Where is Bluejay Diagnostics headquartered?Bluejay Diagnostics is headquartered in United States.
How many employees does Bluejay Diagnostics have?As of today, Bluejay Diagnostics has over 7 employees.
Is Bluejay Diagnostics publicly listed?Yes, Bluejay Diagnostics is a public company listed on Nasdaq.
What is the stock symbol of Bluejay Diagnostics?Bluejay Diagnostics trades under BJDX ticker.
When did Bluejay Diagnostics go public?Bluejay Diagnostics went public in 2021.
Who are competitors of Bluejay Diagnostics?Bluejay Diagnostics main competitors include Epigenomics, Biora Therapeutics, Odyssey Health, Sunniva, Bone Biologics, Luxbright, Brain Scientific, Integragen, Inhalation Sciences SWE, EvokAI.
What is the current market cap of Bluejay Diagnostics?Bluejay Diagnostics' current market cap is $1M.
Is Bluejay Diagnostics profitable?No, Bluejay Diagnostics is not profitable.
How many companies Bluejay Diagnostics has acquired to date?Bluejay Diagnostics hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Bluejay Diagnostics has invested to date?Bluejay Diagnostics hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Bluejay Diagnostics

Lists including Bluejay Diagnostics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial